Bestatin in Resected Lung Cancer A randomized clinical trial

Authors

  • T. Yasumitsu Department of Surgery, Osaka Prefectural Habikino Hospital, Osaka, and the Aichi Cancer Center Research Institute, Nagoya, Japan
  • S. Ohshima Department of Surgery, Osaka Prefectural Habikino Hospital, Osaka, and the Aichi Cancer Center Research Institute, Nagoya, Japan
  • N. Nakano Department of Surgery, Osaka Prefectural Habikino Hospital, Osaka, and the Aichi Cancer Center Research Institute, Nagoya, Japan
  • Y. Kotake Department of Surgery, Osaka Prefectural Habikino Hospital, Osaka, and the Aichi Cancer Center Research Institute, Nagoya, Japan
  • S. Tominaga Department of Surgery, Osaka Prefectural Habikino Hospital, Osaka, and the Aichi Cancer Center Research Institute, Nagoya, Japan

DOI:

https://doi.org/10.3109/02841869009093009

Keywords:

Lung cancer, bestatin, postoperative, adjuvant therapy, immunotherapy, randomized study

Abstract

A randomized study with and without bestatin, a new biological response modifier, was conducted in order to evaluate its survival effect on resected lung cancer. A total of 153 patients (72 with squamous cell carcinoma, 66 with adenocarcinoma, and 15 with other types of cancer) were evaluated. Among the patients with squamous cell carcinoma, the bestatin-treated group had significantly prolonged survival compared to the control group. No significant difference between the two groups was seen in adenocarcinoma.

Downloads

Download data is not yet available.

Downloads

Published

1990-01-01

How to Cite

Yasumitsu, T., Ohshima, S., Nakano, N., Kotake, Y., & Tominaga, S. (1990). Bestatin in Resected Lung Cancer A randomized clinical trial. Acta Oncologica, 29(6), 827–831. https://doi.org/10.3109/02841869009093009

Issue

Vol. 29 No. 6 (1990): Acta Oncologica

Section

Articles